查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1298397

重症肌无力治疗市场：按药物类别、年龄组和分销渠道：2023-2032 年全球机会分析和行业预测

Myasthenia Gravis Treatment Market By Drug class, By Age group, By Distribution channel : Global Opportunity Analysis and Industry Forecast, 2023-2032
出版日期: | 出版商: Allied Market Research | 英文 263 Pages | 商品交期: 2-3个工作天内

价格

2022年全球重症肌无力治疗市场价值为17亿美元，预计2023年至2032年復合年增长率为6.5%，到2032年达到31亿美元。

重症肌无力 (MG) 是一种自身免疫性疾病，抗体攻击并损害神经肌肉接头处的受体，导致肌肉无力和疲劳。抗体还针对乙□胆碱受体 (AChR)，这是一种存在于神经肌肉接头突触后膜中的蛋白质。此外，在某些情况下，抗体可能会靶向与乙□胆碱受体 (AChR) 相关的其他蛋白质，例如肌肉特异性激□ (MuSK)。结果，神经和肌肉之间的沟通受到干扰，导致肌肉无力和疲劳。

重症肌无力最常见的症状包括无力，尤其是眼睛、面部、喉咙和四肢、说话、吞嚥、呼吸困难、上睑下垂、复视以及随着活动而加重的疲劳。目前重症肌无力的治疗方法包括乙□胆碱酯□抑製剂、皮质类固醇、免疫抑製剂、静脉注射免疫球蛋白（IVIg）和单克隆抗体。

Myasthenia Gravis Treatment Market-IMG1

推动重症肌无力治疗市场增长的主要因素是重症肌无力患者数量的增加、自身免疫性疾病诊断技术的进步以及重症肌无力治疗选择的增加。全球重症肌无力患病率上升是推动重症肌无力治疗市场增长的主要因素之一。例如，根据美国重症肌无力基金会的数据，美国每 10 万人中约有 14 至 20 人患有重症肌无力，而且这种疾病在女性中比男性更常见。此外，重症肌无力的患病率在全球范围内不断增加，预计这将推动对该疾病有效治疗的需求。

此外，重症肌无力诊断的增加预计将推动市场增长。重症肌无力是一种罕见且经常被误诊的自身免疫性疾病，会影响神经肌肉接头并导致肌肉无力和疲劳。这种疾病可能很难诊断，因为症状很微妙，而且因人而异。然而，诊断技术的进步使得重症肌无力的诊断更加准确和及时，推动了市场的增长。重症肌无力诊断的激增刺激了对有效治疗的需求，推动了市场的增长。随着越来越多的重症肌无力病例得到早期发现和诊断，越来越需要有效的治疗方法来控制疾病和预防并发症。这导致了对重症肌无力新的、更有效的治疗方法研发的投资增加。

此外，诊断数量的增加提高了患者和医疗保健专业人员对该疾病的认识。此外，越来越多的专门用于治疗重症肌无力的药物处于临床开发阶段，预计也将推动市场增长。随着患有重症肌无力的人数不断增加，对有效治疗的需求也在增加，从而产生了对创新治疗的需求。这种需求促使製药公司和研究机构投资开发针对这种疾病的新疗法，而临床试验已成为测试其安全性和有效性的重要工具。因此，专注于重症肌无力的临床试验的激增预计将通过为患有重症肌无力的患者提供新的和改进的治疗方法来推动重症肌无力治疗市场的增长。

目录

第 1 章 简介

第二章执行摘要

第三章市场概况

  • 市场定义和范围
  • 主要发现
    • 影响因素
    • 主要投资口袋
  • 波特五力分析
    • 供应商的议价能力
    • 买方议价能力
    • 替代品的威胁
    • 新进入者的威胁
    • 竞争强度
  • 市场动态
    • 促进者
      • 对重症肌无力有效治疗的需求不断增长
      • 重症肌无力患病率上升
      • 新药研发进展
    • 阻碍因素
      • 重症肌无力治疗的副作用和高费用
    • 机会
      • 新兴市场的增长机会
  • COVID-19 市场影响分析

4 重症肌无力治疗市场，按药物类别

  • 概述
    • 市场规模和预测
  • 单克隆抗体
    • 主要市场趋势、增长动力和机遇
    • 市场规模/预测：按地区
    • 市场份额分析：按国家分类
  • 静脉注射免疫球蛋白
    • 主要市场趋势、增长动力和机遇
    • 市场规模/预测：按地区
    • 市场份额分析：按国家分类
  • 其他
    • 主要市场趋势、增长动力和机遇
    • 市场规模/预测：按地区
    • 市场份额分析：按国家分类

5 重症肌无力治疗市场（按年龄组）

  • 概述
    • 市场规模和预测
  • 55岁及以下
    • 主要市场趋势、增长动力和机遇
    • 市场规模/预测：按地区
    • 市场份额分析：按国家分类
  • 55+
    • 主要市场趋势、增长动力和机遇
    • 市场规模/预测：按地区
    • 市场份额分析：按国家

6 重症肌无力治疗市场（按分销渠道）

  • 概述
    • 市场规模及预测
  • 医院药房
    • 主要市场趋势、增长动力和机遇
    • 市场规模/预测：按地区
    • 市场份额分析：按国家分类
  • 药店和零售药店
    • 主要市场趋势、增长动力和机遇
    • 市场规模/预测：按地区
    • 市场份额分析：按国家分类
  • 在线提供商
    • 主要市场趋势、增长动力和机遇
    • 市场规模/预测：按地区
    • 市场份额分析：按国家分类

7 重症肌无力治疗市场，按地区

  • 概述
    • 市场规模/预测：按地区
  • 北美
    • 主要趋势和机遇
    • 市场规模和预测：按药物类别
    • 市场规模/预测：按年龄段
    • 市场规模和预测：按分销渠道划分
    • 市场规模/预测：按国家
      • 美国
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测：按功效等级划分
      • 市场规模/预测：按年龄段
      • 市场规模和预测：按分销渠道划分
      • 加拿大
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测：按治疗类别
      • 市场规模/预测：按年龄段
      • 市场规模和预测：按分销渠道划分
      • 墨西哥
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测：按治疗类别
      • 市场规模/预测：按年龄段
      • 市场规模和预测：按分销渠道划分
  • 欧洲
    • 主要趋势和机遇
    • 市场规模/预测：按功效等级划分
    • 市场规模/预测：按年龄段
    • 市场规模和预测：按分销渠道划分
    • 市场规模/预测：按国家
      • 德国
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测：按功效等级划分
      • 市场规模/预测：按年龄段
      • 市场规模和预测：按分销渠道划分
      • 法国
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测：按治疗类别
      • 市场规模/预测：按年龄段
      • 市场规模和预测：按分销渠道划分
      • 英国
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测：按治疗类别
      • 市场规模/预测：按年龄段
      • 市场规模和预测：按分销渠道划分
      • 意大利
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测：按治疗类别
      • 市场规模/预测：按年龄段
      • 市场规模和预测：按分销渠道划分
      • 西班牙
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测：按治疗类别
      • 市场规模/预测：按年龄段
      • 市场规模和预测：按分销渠道划分
      • 欧洲其他地区
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测：按功效等级划分
      • 市场规模/预测：按年龄段
      • 市场规模和预测：按分销渠道划分
  • 亚太地区
    • 主要趋势和机遇
    • 市场规模/预测：按治疗类别
    • 市场规模/预测：按年龄段
    • 市场规模和预测：按分销渠道划分
    • 市场规模/预测：按国家
      • 日本
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测：按治疗类别
      • 市场规模/预测：按年龄段
      • 市场规模和预测：按分销渠道划分
      • 中国
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测：按治疗类别
      • 市场规模/预测：按年龄段
      • 市场规模和预测：按分销渠道划分
      • 印度
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测：按治疗类别
      • 市场规模/预测：按年龄段
      • 市场规模和预测：按分销渠道划分
      • 亚太其他地区
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测：按治疗类别
      • 市场规模/预测：按年龄段
      • 市场规模和预测：按分销渠道划分
  • 拉丁美洲/中东/非洲
    • 主要趋势和机遇
    • 市场规模/预测：按治疗类别
    • 市场规模/预测：按年龄段
    • 市场规模和预测：按分销渠道划分
    • 市场规模/预测：按国家
      • 拉丁美洲
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测：按功效等级划分
      • 市场规模/预测：按年龄段
      • 市场规模和预测：按分销渠道划分
      • 中东/非洲
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测：按治疗类别
      • 市场规模/预测：按年龄段
      • 市场规模和预测：按分销渠道划分

第8章 竞争格局

  • 介绍
  • 关键成功策略
  • 10大公司产品图
  • 比赛仪表板
  • 比赛热图
  • 2022 年顶级公司定位

第九章公司简介

  • Zydus Lifesciences Limited
  • Novartis AG
  • AstraZeneca
  • Bausch Health Companies, Inc.
  • CSL Limited
  • Grifols, S.A.
  • Octapharma AG
  • Astellas Pharma Inc.
  • Kedrion, SpA
  • F. Hoffmann-La Roche Ltd.
Product Code: A11194

The global myasthenia gravis treatment market was valued at $1.7 billion in 2022, and is projected to reach $3.1 billion by 2032, growing at a CAGR of 6.5% from 2023 to 2032.

Myasthenia gravis (MG) is an autoimmune disease caused by antibodies that attack and damage the receptors at the neuromuscular junction, leading to muscle weakness and fatigue. In addition, the antibodies target the acetylcholine receptor (AChR), which is a protein located on the postsynaptic membrane of the neuromuscular junction. Moreover, in some cases, the antibodies may target other proteins related to the acetylcholine receptor (AChR), such as muscle-specific kinase (MuSK). This leads to impaired communication between the nerve and muscle, which results in muscle weakness and fatigue.

The most common symptoms of myasthenia gravis include muscle weakness, particularly in the eyes, face, throat & limbs, difficulty speaking, swallowing, or breathing, drooping eyelids, double vision, and fatigue that worsens with activity. Currently, there are several drugs available for the treatment of myasthenia gravis, such as acetylcholinesterase inhibitors, corticosteroids, immunosuppressants, intravenous immunoglobulin (IVIg), and monoclonal antibodies.

Myasthenia Gravis Treatment Market - IMG1

The major factor driving the growth of myasthenia gravis treatment market are increase in number of patients suffering from myasthenia gravis, advancements in diagnosis of autoimmune disorders, and rise in availability of treatment options for myasthenia gravis. The rise in prevalence of myasthenia gravis worldwide is one of the primary drivers for the growth of the myasthenia gravis treatment market. For instance, according to the Myasthenia Gravis Foundation of America, approximately 14 to 20 out of 100,000 people in the U.S. are affected by myasthenia gravis, and the disease is more common in women than men. Moreover, the incidence of myasthenia gravis has increased globally, which is expected to drive the demand for effective treatments for the disease.

Furthermore, increase in the diagnosis of myasthenia gravis is expected to fuel the market growth. Myasthenia gravis is a rare and often misdiagnosed autoimmune disorder that affects the neuromuscular junction, leading to muscle weakness and fatigue. The disease can be challenging to diagnose, as symptoms may be subtle or vary greatly from person to person. However, advancements in diagnostic techniques have led to more accurate and timely diagnosis of myasthenia gravis, which drives the market growth. The surge in the diagnosis of myasthenia gravis has increased the demand for effective treatments and fosters market growth. As more cases of myasthenia gravis are identified and diagnosed earlier, there is a greater need for effective treatments to manage the disease and prevent complications. This has led to increased investment in R&D of new and more effective treatments for myasthenia gravis.

Furthermore, the increase in diagnosis has led to greater awareness of the disease among patients and healthcare professionals. In addition, increase in number of drugs in clinical stages of development, focused on treatment of myasthenia gravis is anticipated to boost the growth of market. As the number of people affected by myasthenia gravis continues to increase, the demand for effective treatments rises, resulting in need for innovative therapies. This demand drives the pharmaceutical companies and research institutions to invest in the development of new treatments for the disease, with clinical trials serving as a critical tool for testing their safety and efficacy. Thus, upsurge in number of clinical trials focused on myasthenia gravis is expected to drive the growth of the myasthenia gravis treatment market by providing new and improved treatments for patients suffering from myasthenia gravis disease.

The myasthenia gravis treatment market is segmented into drug class, age group, distribution channel, and region. On the basis of drug class, the market is categorized into cholinesterase inhibitors, immunosuppressants, monoclonal antibodies, intravenous immunoglobulin (IVIg), and others. On the basis of age group, the market is bifurcated into below 50 years and above 50 years. On the basis of distribution channel, the market is segregated into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major key players that operate in the global myasthenia gravis treatment market are: F. Hoffmann-La Roche Ltd., AstraZeneca, Novartis AG, Zydus Lifesciences Limited, Bausch Health Companies, Inc., CSL Limited, Grifols, S.A., Octapharma AG, Astellas Pharma Inc., and Kedrion, SpA. The key players have adopted strategies such as acquisition, agreement, strategic alliance, product approval, and expansion to expand their product portfolio.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the myasthenia gravis treatment market analysis from 2022 to 2032 to identify the prevailing myasthenia gravis treatment market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the myasthenia gravis treatment market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global myasthenia gravis treatment market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Drug class

  • Intravenous immunoglobulin
  • Others
  • Monoclonal antibodies

By Age group

  • Below 55 years
  • Above 55 years

By Distribution channel

  • Hospital pharmacies
  • Drug store and retail pharmacies
  • Online providers

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Rest of Asia-Pacific
  • LAMEA
    • Latin America
    • Middle East And Africa

Key Market Players:

    • Astellas Pharma Inc.
    • AstraZeneca
    • Bausch Health Companies, Inc.
    • CSL Limited
    • F. Hoffmann-La Roche Ltd.
    • Grifols, S.A.
    • Kedrion, SpA
    • Novartis AG
    • Octapharma AG
    • Zydus Lifesciences Limited

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Bargaining power of suppliers
    • 3.3.2. Bargaining power of buyers
    • 3.3.3. Threat of substitutes
    • 3.3.4. Threat of new entrants
    • 3.3.5. Intensity of rivalry
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Rise in demand of effective treatments for myasthenia gravis
      • 3.4.1.2. Surge in prevalence of myasthenia gravis
      • 3.4.1.3. Advancements in R&D of novel drugs
    • 3.4.2. Restraints
      • 3.4.2.1. Side effects and high cost associated with treatments for myasthenia gravis
    • 3.4.3. Opportunities
      • 3.4.3.1. Growth opportunities in emerging markets
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Monoclonal antibodies
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Intravenous immunoglobulin
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Others
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country

CHAPTER 5: MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Below 55 years
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Above 55 years
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country

CHAPTER 6: MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospital pharmacies
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Drug store and retail pharmacies
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Online providers
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: MYASTHENIA GRAVIS TREATMENT MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key trends and opportunities
    • 7.2.2. Market size and forecast, by Drug class
    • 7.2.3. Market size and forecast, by Age group
    • 7.2.4. Market size and forecast, by Distribution channel
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Key market trends, growth factors and opportunities
      • 7.2.5.1.2. Market size and forecast, by Drug class
      • 7.2.5.1.3. Market size and forecast, by Age group
      • 7.2.5.1.4. Market size and forecast, by Distribution channel
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Key market trends, growth factors and opportunities
      • 7.2.5.2.2. Market size and forecast, by Drug class
      • 7.2.5.2.3. Market size and forecast, by Age group
      • 7.2.5.2.4. Market size and forecast, by Distribution channel
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Key market trends, growth factors and opportunities
      • 7.2.5.3.2. Market size and forecast, by Drug class
      • 7.2.5.3.3. Market size and forecast, by Age group
      • 7.2.5.3.4. Market size and forecast, by Distribution channel
  • 7.3. Europe
    • 7.3.1. Key trends and opportunities
    • 7.3.2. Market size and forecast, by Drug class
    • 7.3.3. Market size and forecast, by Age group
    • 7.3.4. Market size and forecast, by Distribution channel
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Key market trends, growth factors and opportunities
      • 7.3.5.1.2. Market size and forecast, by Drug class
      • 7.3.5.1.3. Market size and forecast, by Age group
      • 7.3.5.1.4. Market size and forecast, by Distribution channel
      • 7.3.5.2. France
      • 7.3.5.2.1. Key market trends, growth factors and opportunities
      • 7.3.5.2.2. Market size and forecast, by Drug class
      • 7.3.5.2.3. Market size and forecast, by Age group
      • 7.3.5.2.4. Market size and forecast, by Distribution channel
      • 7.3.5.3. UK
      • 7.3.5.3.1. Key market trends, growth factors and opportunities
      • 7.3.5.3.2. Market size and forecast, by Drug class
      • 7.3.5.3.3. Market size and forecast, by Age group
      • 7.3.5.3.4. Market size and forecast, by Distribution channel
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Key market trends, growth factors and opportunities
      • 7.3.5.4.2. Market size and forecast, by Drug class
      • 7.3.5.4.3. Market size and forecast, by Age group
      • 7.3.5.4.4. Market size and forecast, by Distribution channel
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Key market trends, growth factors and opportunities
      • 7.3.5.5.2. Market size and forecast, by Drug class
      • 7.3.5.5.3. Market size and forecast, by Age group
      • 7.3.5.5.4. Market size and forecast, by Distribution channel
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Key market trends, growth factors and opportunities
      • 7.3.5.6.2. Market size and forecast, by Drug class
      • 7.3.5.6.3. Market size and forecast, by Age group
      • 7.3.5.6.4. Market size and forecast, by Distribution channel
  • 7.4. Asia-Pacific
    • 7.4.1. Key trends and opportunities
    • 7.4.2. Market size and forecast, by Drug class
    • 7.4.3. Market size and forecast, by Age group
    • 7.4.4. Market size and forecast, by Distribution channel
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Key market trends, growth factors and opportunities
      • 7.4.5.1.2. Market size and forecast, by Drug class
      • 7.4.5.1.3. Market size and forecast, by Age group
      • 7.4.5.1.4. Market size and forecast, by Distribution channel
      • 7.4.5.2. China
      • 7.4.5.2.1. Key market trends, growth factors and opportunities
      • 7.4.5.2.2. Market size and forecast, by Drug class
      • 7.4.5.2.3. Market size and forecast, by Age group
      • 7.4.5.2.4. Market size and forecast, by Distribution channel
      • 7.4.5.3. India
      • 7.4.5.3.1. Key market trends, growth factors and opportunities
      • 7.4.5.3.2. Market size and forecast, by Drug class
      • 7.4.5.3.3. Market size and forecast, by Age group
      • 7.4.5.3.4. Market size and forecast, by Distribution channel
      • 7.4.5.4. Rest of Asia-Pacific
      • 7.4.5.4.1. Key market trends, growth factors and opportunities
      • 7.4.5.4.2. Market size and forecast, by Drug class
      • 7.4.5.4.3. Market size and forecast, by Age group
      • 7.4.5.4.4. Market size and forecast, by Distribution channel
  • 7.5. LAMEA
    • 7.5.1. Key trends and opportunities
    • 7.5.2. Market size and forecast, by Drug class
    • 7.5.3. Market size and forecast, by Age group
    • 7.5.4. Market size and forecast, by Distribution channel
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Latin America
      • 7.5.5.1.1. Key market trends, growth factors and opportunities
      • 7.5.5.1.2. Market size and forecast, by Drug class
      • 7.5.5.1.3. Market size and forecast, by Age group
      • 7.5.5.1.4. Market size and forecast, by Distribution channel
      • 7.5.5.2. Middle East And Africa
      • 7.5.5.2.1. Key market trends, growth factors and opportunities
      • 7.5.5.2.2. Market size and forecast, by Drug class
      • 7.5.5.2.3. Market size and forecast, by Age group
      • 7.5.5.2.4. Market size and forecast, by Distribution channel

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

  • 9.1. Zydus Lifesciences Limited
    • 9.1.1. Company overview
    • 9.1.2. Key Executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
  • 9.2. Novartis AG
    • 9.2.1. Company overview
    • 9.2.2. Key Executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
  • 9.3. AstraZeneca
    • 9.3.1. Company overview
    • 9.3.2. Key Executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
    • 9.3.7. Key strategic moves and developments
  • 9.4. Bausch Health Companies, Inc.
    • 9.4.1. Company overview
    • 9.4.2. Key Executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Business performance
  • 9.5. CSL Limited
    • 9.5.1. Company overview
    • 9.5.2. Key Executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Business performance
    • 9.5.7. Key strategic moves and developments
  • 9.6. Grifols, S.A.
    • 9.6.1. Company overview
    • 9.6.2. Key Executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
    • 9.6.6. Business performance
    • 9.6.7. Key strategic moves and developments
  • 9.7. Octapharma AG
    • 9.7.1. Company overview
    • 9.7.2. Key Executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
  • 9.8. Astellas Pharma Inc.
    • 9.8.1. Company overview
    • 9.8.2. Key Executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
  • 9.9. Kedrion, SpA
    • 9.9.1. Company overview
    • 9.9.2. Key Executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Business performance
    • 9.9.7. Key strategic moves and developments
  • 9.10. F. Hoffmann-La Roche Ltd.
    • 9.10.1. Company overview
    • 9.10.2. Key Executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance

LIST OF TABLES

  • TABLE 01. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 02. MYASTHENIA GRAVIS TREATMENT MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. MYASTHENIA GRAVIS TREATMENT MARKET FOR INTRAVENOUS IMMUNOGLOBULIN, BY REGION, 2022-2032 ($MILLION)
  • TABLE 04. MYASTHENIA GRAVIS TREATMENT MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 05. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 06. MYASTHENIA GRAVIS TREATMENT MARKET FOR BELOW 55 YEARS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 07. MYASTHENIA GRAVIS TREATMENT MARKET FOR ABOVE 55 YEARS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 08. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 09. MYASTHENIA GRAVIS TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. MYASTHENIA GRAVIS TREATMENT MARKET FOR DRUG STORE AND RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. MYASTHENIA GRAVIS TREATMENT MARKET FOR ONLINE PROVIDERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. MYASTHENIA GRAVIS TREATMENT MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. NORTH AMERICA MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 14. NORTH AMERICA MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 15. NORTH AMERICA MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 16. NORTH AMERICA MYASTHENIA GRAVIS TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 17. U.S. MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 18. U.S. MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 19. U.S. MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 20. CANADA MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 21. CANADA MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 22. CANADA MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 23. MEXICO MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 24. MEXICO MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 25. MEXICO MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 26. EUROPE MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 27. EUROPE MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 28. EUROPE MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 29. EUROPE MYASTHENIA GRAVIS TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 30. GERMANY MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 31. GERMANY MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 32. GERMANY MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 33. FRANCE MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 34. FRANCE MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 35. FRANCE MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 36. UK MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 37. UK MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 38. UK MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 39. ITALY MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 40. ITALY MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 41. ITALY MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 42. SPAIN MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 43. SPAIN MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 44. SPAIN MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 45. REST OF EUROPE MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 46. REST OF EUROPE MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 47. REST OF EUROPE MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 48. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 49. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 50. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 51. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 52. JAPAN MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 53. JAPAN MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 54. JAPAN MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 55. CHINA MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 56. CHINA MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 57. CHINA MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 58. INDIA MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 59. INDIA MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 60. INDIA MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 61. REST OF ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 62. REST OF ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 63. REST OF ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 64. LAMEA MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 65. LAMEA MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 66. LAMEA MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 67. LAMEA MYASTHENIA GRAVIS TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 68. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 69. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 70. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 71. MIDDLE EAST AND AFRICA MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 72. MIDDLE EAST AND AFRICA MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 73. MIDDLE EAST AND AFRICA MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 74. ZYDUS LIFESCIENCES LIMITED: KEY EXECUTIVES
  • TABLE 75. ZYDUS LIFESCIENCES LIMITED: COMPANY SNAPSHOT
  • TABLE 76. ZYDUS LIFESCIENCES LIMITED: PRODUCT SEGMENTS
  • TABLE 77. ZYDUS LIFESCIENCES LIMITED: PRODUCT PORTFOLIO
  • TABLE 78. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 79. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 80. NOVARTIS AG: PRODUCT SEGMENTS
  • TABLE 81. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 82. ASTRAZENECA: KEY EXECUTIVES
  • TABLE 83. ASTRAZENECA: COMPANY SNAPSHOT
  • TABLE 84. ASTRAZENECA: PRODUCT SEGMENTS
  • TABLE 85. ASTRAZENECA: PRODUCT PORTFOLIO
  • TABLE 86. ASTRAZENECA: KEY STRATERGIES
  • TABLE 87. BAUSCH HEALTH COMPANIES, INC.: KEY EXECUTIVES
  • TABLE 88. BAUSCH HEALTH COMPANIES, INC.: COMPANY SNAPSHOT
  • TABLE 89. BAUSCH HEALTH COMPANIES, INC.: PRODUCT SEGMENTS
  • TABLE 90. BAUSCH HEALTH COMPANIES, INC.: PRODUCT PORTFOLIO
  • TABLE 91. CSL LIMITED: KEY EXECUTIVES
  • TABLE 92. CSL LIMITED: COMPANY SNAPSHOT
  • TABLE 93. CSL LIMITED: PRODUCT SEGMENTS
  • TABLE 94. CSL LIMITED: PRODUCT PORTFOLIO
  • TABLE 95. CSL LIMITED: KEY STRATERGIES
  • TABLE 96. GRIFOLS, S.A.: KEY EXECUTIVES
  • TABLE 97. GRIFOLS, S.A.: COMPANY SNAPSHOT
  • TABLE 98. GRIFOLS, S.A.: PRODUCT SEGMENTS
  • TABLE 99. GRIFOLS, S.A.: PRODUCT PORTFOLIO
  • TABLE 100. GRIFOLS, S.A.: KEY STRATERGIES
  • TABLE 101. OCTAPHARMA AG: KEY EXECUTIVES
  • TABLE 102. OCTAPHARMA AG: COMPANY SNAPSHOT
  • TABLE 103. OCTAPHARMA AG: PRODUCT SEGMENTS
  • TABLE 104. OCTAPHARMA AG: PRODUCT PORTFOLIO
  • TABLE 105. ASTELLAS PHARMA INC.: KEY EXECUTIVES
  • TABLE 106. ASTELLAS PHARMA INC.: COMPANY SNAPSHOT
  • TABLE 107. ASTELLAS PHARMA INC.: PRODUCT SEGMENTS
  • TABLE 108. ASTELLAS PHARMA INC.: PRODUCT PORTFOLIO
  • TABLE 109. KEDRION, SPA: KEY EXECUTIVES
  • TABLE 110. KEDRION, SPA: COMPANY SNAPSHOT
  • TABLE 111. KEDRION, SPA: PRODUCT SEGMENTS
  • TABLE 112. KEDRION, SPA: PRODUCT PORTFOLIO
  • TABLE 113. KEDRION, SPA: KEY STRATERGIES
  • TABLE 114. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
  • TABLE 115. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
  • TABLE 116. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
  • TABLE 117. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01. MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032
  • FIGURE 03. TOP INVESTMENT POCKETS IN MYASTHENIA GRAVIS TREATMENT MARKET (2023-2032)
  • FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. LOW BARGAINING POWER OF BUYERS
  • FIGURE 06. LOW THREAT OF SUBSTITUTES
  • FIGURE 07. LOW THREAT OF NEW ENTRANTS
  • FIGURE 08. LOW INTENSITY OF RIVALRY
  • FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALMYASTHENIA GRAVIS TREATMENT MARKET
  • FIGURE 10. MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF MYASTHENIA GRAVIS TREATMENT MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF MYASTHENIA GRAVIS TREATMENT MARKET FOR INTRAVENOUS IMMUNOGLOBULIN, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF MYASTHENIA GRAVIS TREATMENT MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 14. MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF MYASTHENIA GRAVIS TREATMENT MARKET FOR BELOW 55 YEARS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF MYASTHENIA GRAVIS TREATMENT MARKET FOR ABOVE 55 YEARS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 17. MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF MYASTHENIA GRAVIS TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF MYASTHENIA GRAVIS TREATMENT MARKET FOR DRUG STORE AND RETAIL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF MYASTHENIA GRAVIS TREATMENT MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 21. MYASTHENIA GRAVIS TREATMENT MARKET BY REGION, 2022
  • FIGURE 22. U.S. MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 23. CANADA MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 24. MEXICO MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 25. GERMANY MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 26. FRANCE MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 27. UK MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 28. ITALY MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 29. SPAIN MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 30. REST OF EUROPE MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 31. JAPAN MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 32. CHINA MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 33. INDIA MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 34. REST OF ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 35. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 36. MIDDLE EAST AND AFRICA MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 37. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 38. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 39. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 40. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 41. COMPETITIVE DASHBOARD
  • FIGURE 42. COMPETITIVE HEATMAP: MYASTHENIA GRAVIS TREATMENT MARKET
  • FIGURE 43. TOP PLAYER POSITIONING, 2022
  • FIGURE 44. ZYDUS LIFESCIENCES LIMITED: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 45. ZYDUS LIFESCIENCES LIMITED: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 46. ZYDUS LIFESCIENCES LIMITED: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 47. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 48. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 49. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 50. ASTRAZENECA: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 51. ASTRAZENECA: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 52. BAUSCH HEALTH COMPANIES, INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 53. BAUSCH HEALTH COMPANIES, INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 54. BAUSCH HEALTH COMPANIES, INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 55. CSL LIMITED: SALES REVENUE, 2020-2022 ($MILLION)
  • FIGURE 56. CSL LIMITED: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 57. CSL LIMITED: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 58. GRIFOLS, S.A.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 59. GRIFOLS, S.A.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 60. GRIFOLS, S.A.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 61. OCTAPHARMA AG: SALES REVENUE, 2020-2022 ($MILLION)
  • FIGURE 62. ASTELLAS PHARMA INC.: SALES REVENUE, 2020-2022 ($MILLION)
  • FIGURE 63. ASTELLAS PHARMA INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 64. KEDRION, SPA: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 65. F. HOFFMANN-LA ROCHE LTD.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 66. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 67. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY REGION, 2022 (%)